MANILA – The Food and Drug Administration (FDA) has streamlined the regulatory process for pharmaceutical exports and active pharmaceutical ingredients intended for export.
In a news release on Monday, the FDA stated that Administrative Order (AO) No. 2024-0012, titled “Prescribing the Rules and Regulations on the Registration of Pharmaceutical Products and Active Pharmaceutical Ingredients Intended Solely for Export,” was issued following the directive of President Ferdinand R. Marcos Jr. to strengthen the health sector and expedite the distribution of medicines to the public.
The FDA noted that the rules outlined in the administrative order ensure that pharmaceutical products will not be adulterated or misbranded if they comply with the foreign purchaser’s standards, follow the laws of the receiving country, and are properly labeled “intended for export.”
The administrative order provides a significant boost for current manufacturers and future investors, enhancing the position of the Philippines as a prime hub for pharmaceutical manufacturing, the FDA said.
Under Section 15 of Executive Order (EO) No. 175 s. 1987, no medicine or medical equipment may be created, sold, imported, exported, or distributed without being registered according to the guidelines set by the Department of Health.
The EO amended Republic Act (RA) No. 3720, known as the “Food, Drug, and Cosmetic Act,” and RA No. 9711, known as the “Strengthening of the Food and Drug Administration (FDA) Act of 2009.”
Pharmaceutical products designated for export must also comply with the regulations of the National Drug Regulatory Authority of the receiving country.(PNA)